Merck & Co., Inc. (FRA:6MK)
70.10
+0.90 (1.30%)
Last updated: Jun 10, 2025
Merck & Co. Revenue
Merck & Co. had revenue of $15.53B USD in the quarter ending March 31, 2025, a decrease of -1.56%. This brings the company's revenue in the last twelve months to $63.92B, up 4.10% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$63.92B
Revenue Growth
+4.10%
P/S Ratio
2.97
Revenue / Employee
$852.29K
Employees
75,000
Market Cap
175.63B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.15B |
Siemens Aktiengesellschaft | 77.82B |
Deutsche Telekom AG | 120.25B |
Allianz SE | 109.03B |
Rheinmetall AG | 10.48B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
Siemens Energy AG | 37.44B |
Siemens Healthineers AG | 23.14B |
Merck & Co. News
- 2 days ago - China’s Center for Drug Evaluation Accepts Merck’s Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor - Business Upturn
- 3 days ago - FDA approves Mercks RSV shot for infants, ramping up competition with Sanofi and AstraZeneca - CNBC
- 3 days ago - US FDA approves Merck's RSV antibody for infants - Reuters
- 3 days ago - U.S. FDA Approves Merck’s ENFLONSIA (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season - Wallstreet:Online
- 3 days ago - U.S. FDA Approves Merck's ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season - Business Wire
- 3 days ago - Price Over Earnings Overview: Merck & Co - Benzinga
- 3 days ago - Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials - Benzinga
- 3 days ago - Merck succeeds in late-stage trials for cholesterol drug - Seeking Alpha